RecruitingNCT04558593

Surveillance of Complex Renal Cysts - The SOCRATIC Study


Sponsor

Université de Sherbrooke

Enrollment

330 participants

Start Date

Feb 2, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

One third of individuals aged \>60 years will be diagnosed with at least one renal cyst following abdominal imaging. These cystic lesions are categorized according to the Bosniak classification which categorizes cysts according to their degree of complexity and risk of malignancy. Growing evidence suggests that a significant proportion of Bosniak III and IV cysts are benign and that the malignant ones present low metastatic potential. Since renal surgery carries substantial morbidity (20%) and potential mortality (0.5%), active surveillance has gained attention as a potential tradeoff to surgery to overcome overtreatment. Therefore, prospective studies of long-term follow-up are needed to confirm the oncologic safety of this strategy for patients with Bosniak III/IV cysts. This is an multicenter prospective observational longitudinal study. The main objective is to compare the 5-year follow-up cancer-specific survival between the active surveillance and the surgical groups.


Eligibility

Min Age: 18 Years

Inclusion Criteria10

  • years old and older;
  • diagnosed with a Bosniak III or IV cyst (classification 2019);
  • size of cystic component ≤7cm;
  • cyst wall/septum nodule (obtuse margin of protrusion) \<10mm (perpendicular axis) or nodular/solid component ≤2 cm in any axis;
  • life expectancy \>5 years (by physician's estimate);
  • new diagnosis ≤ 12 months from accrual date;
  • currently asymptomatic from the disease;
  • deemed fit enough for surgery;
  • willingness and ability to complete questionnaires in either French or English;
  • able and willing to provide informed consent

Exclusion Criteria8

  • history of a hereditary renal cancer syndrome;
  • presence of polycystic kidney disease;
  • any prior history of RCC;
  • received systemic therapy for another malignancy within the 12 months prior to accrual;
  • uncontrolled medical illness including infections, hypertension, arrhythmias, heart failure, or myocardial infarction/unstable angina within 6 months that would predispose to immediate surgical therapy;
  • metastatic disease or evidence of vascular or nodal disease;
  • unwillingness to undergo monitoring and imaging studies;
  • any contra-indication(s) to contrast-enhanced imaging (estimated glomerular filtration rate \<30min/mL)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREActive surveillance

Per standard of care: Imaging and blood tests every 6 months (3 first years) and annually (following years)

PROCEDURESurgery

Per standard of care: partial or full resection of the kidney, imaging annually


Locations(18)

Prostate Cancer Center

Calgary, Alberta, Canada

Northern Alberta Urology Center

Edmonton, Alberta, Canada

Vancouver Prostate Centre

Vancouver, British Columbia, Canada

Mens Health Clinic

Winnipeg, Manitoba, Canada

Nova Scotia Health Authority

Halifax, Nova Scotia, Canada

St-Joseph's Hospital

Hamilton, Ontario, Canada

The Ottawa Hospital

Ottawa, Ontario, Canada

Thunder Bay Health Sciences Center

Thunder Bay, Ontario, Canada

Princess Margaret Hospital

Toronto, Ontario, Canada

Woodstock hospital

Woodstock, Ontario, Canada

Centre intégré de santé et de services sociaux de Chaudière-Appalaches - Hôtel-Dieu de Lévis

Lévis, Quebec, Canada

CHUM

Montreal, Quebec, Canada

Hôpital Maisonneuve-Rosemont (CISSS-EIMtl)

Montreal, Quebec, Canada

McGill University Health Centre

Montreal, Quebec, Canada

CHU de Québec - Université Laval

Québec, Quebec, Canada

Centre de recherche du Centre hospitalier Universitaire de Sherbrooke

Sherbrooke, Quebec, Canada

CIUSSS Mauricie-Centre-du-Québec

Trois-Rivières, Quebec, Canada

CHU Bordeaux (URO-CCR)

Bordeaux, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04558593